VERIFIEDMint Markets·8 Oct 2026neutral

Pharma stocks to buy ahead of Q2 results: Acutaas Chemicals, Mankind Pharma, Ipca Labs - Max upside? Target price

AI Summary

·Pharma exporters may benefit from rupee depreciation ahead of Q2 results.
·Elevated freight and input costs pose potential risks for the sector.
·InCred identifies potential pressure on Dr Reddy’s, Divi’s, Lupin, Cipla, Torrent Pharma, and Blue Jet Healthcare in Q2FY27.